Screener
McKesson MCK North American Pharmaceutical — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Oncology & Multispecialty | Prescription Technology Solutions | Medical-Surgical Solutions | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 | $2,781 | $3,963 | $2,065 | $2,507 | $11,316 |
| Goodwill acquired | — | 13 | — | — | 13 |
| Disposals | — | (2) | — | — | (2) |
| Foreign currency translation adjustments, net | (26) | — | — | — | (26) |
| Other adjustments (1) | — | (23) | — | — | (23) |
| Balance, June 30, 2026 | $2,755 | $3,951 | $2,065 | $2,507 | $11,278 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's north american pharmaceutical — goodwill?
- McKesson (MCK) reported north american pharmaceutical — goodwill of $2.76B in Q2 2026.
- What does north american pharmaceutical — goodwill mean?
- This metric represents the intangible asset value recorded on the balance sheet for the North American Pharmaceutical segment, arising from the acquisition of other businesses. It reflects the premium paid over the fair value of net identifiable assets, representing brand value, customer relationships, and synergies.
Ask your AI about McKesson's north american pharmaceutical — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude